Scientific Background and Reference Sources
ACS. (2024). What Is Non-Small Cell Lung Cancer? m https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html
Al-Ahmadi, A., Ardeshir-Larijani, F., Fu, P., Cao, S., Lipka, M. B., Dowlati, A., & Bruno, D. S. (2021). Next Generation Sequencing of Advanced Non– Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. Clinical Lung Cancer, 22(1), 16-22. e11. https://doi.org/10.1016/j.cllc.2020.08.004
Boeckx, B., Shahi, R. B., Smeets, D., De Brakeleer, S., Decoster, L., Van Brussel, T., . . . De Greve, J. (2020). The genomic landscape of nonsmall cell lung carcinoma in never smokers. Int J Cancer, 146(11), 3207-3218. https://doi.org/10.1002/ijc.32797
Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018). Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. Journal for ImmunoTherapy of Cancer, 6(1), 35. https://doi.org/10.1186/s40425-018-0342-x
FDA. (2004). HIGHLIGHTS OF PRESCRIBING INFORMATION. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
FDA. (2016). cobas EGFR Mutation Test v2. FDA. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/cobas-egfr-mutation-test-v
FDA. (2023). List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools
Fong, K. M., Zimmerman, P. V., & Smith, P. J. (1995). Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res, 55(1), 28-30. https://pubmed.ncbi.nlm.nih.gov/7805035
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., . . . Mino-Kenudson, M. (2016). EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res, 22(18), 4585-4593. https://doi.org/10.1158/1078-0432.Ccr-15-3101
Guardant. (2021). Guardant360® CDx liquid biopsy is poised to bring the promise of precision oncology to more advanced cancer patients. https://guardanthealth.com/wp-content/uploads/Backgrounder-for-Media-Guardant360-CDx.pdf
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Masters, G. (2017). Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 35(30), 3484-3515. https://doi.org/10.1200/JCO.2017.74.6065
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., & Reck, M. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1016/j.annonc.2022.12.009
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., . . . Sundaram, B. (2018). Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Clinical Oncology, 36(9), 911-919. https://doi.org/10.1200/JCO.2017.76.7293
Kris, M. G., Gaspar, L. E., Chaft, J. E., Kennedy, E. B., Azzoli, C. G., Ellis, P. M., . . . Weyant, M. (2017). Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol, 35(25), 2960-2974. https://doi.org/10.1200/jco.2017.72.4401
Lemery, S., Keegan, P., & Pazdur, R. (2017). First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med, 377(15), 1409-1412. https://doi.org/10.1056/NEJMp1709968
Li, X., Cai, W., Yang, G., Su, C., Ren, S., Zhao, C., . . . Hirsch, F. R. (2017). Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. J Thorac Oncol, 12(9), 1388-1397. https://doi.org/10.1016/j.jtho.2017.06.006
Lin, J. H., Lin, D., Xu, L., Wang, Q., Hu, H. H., Xu, H. P., & He, Z. Y. (2017). The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Oncotarget, 8(2), 3412-3421. https://doi.org/10.18632/oncotarget.13787
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Yatabe, Y. (2018). Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn, 20(2), 129-159. https://doi.org/10.1016/j.jmoldx.2017.11.004
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., . . . Ladanyi, M. (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med, 137(6), 828-860. https://doi.org/10.5858/arpa.2012-0720-OA
Midthun, D. (2022. 4/28/22). Clinical manifestations of lung cancer. https://www.uptodate.com/contents/clinical-manifestations-of-lung-cancer?
NCCN. (2024). NCCN Clinical Practice Guidelines in Oncology; Non-Small Cell Lung Cancer v4.2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
NICE. (2013, August 14, 2013). EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. https://www.nice.org.uk/guidance/dg9/chapter/1-Recommendations
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Peters, S. (2016). Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://doi.org/10.1093/annonc/mdw326
Peled, M., Bar, J., Avni, L., Chatterji, S., Somech, D., Dvir, A., . . . Onn, A. (2020). Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series.The Israel Medical Association journal: IMAJ, 22(12), 784-787. http://europepmc.org/abstract/MED/33381953
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P. J., Quoix, E., Baik, C. S., . . . Johnson, B. E. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol, 17(7), 984-993. https://doi.org/10.1016/s1470-2045(16)30146-2
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., . . . Peters, S. (2020). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 29(Suppl 4), iv192-iv237. doi:10.1093/annonc/mdy275
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., . . . Peters, S. (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 28(suppl_4), iv1-iv21. https://doi.org/10.1093/annonc/mdx222
Sequist, L., & Neal, J. (2024, February 1, 2024). Personalized, genotype-directed therapy for advanced non-small cell lung cancer - https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer
Shea, M., Costa, D. B., & Rangachari, D. (2016). Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis, 10(2), 113-129. https://doi.org/10.1177/1753465815617871
Siena, S., Doebele, R. C., Shaw, A. T., Karapetis, C. S., Tan, D. S.-W., Cho, B. C., . . . Drilon, A. E. (2019). Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. Journal of Clinical Oncology, 37(15_suppl), 3017-3017. https://doi.org/10.1200/JCO.2019.37.15_suppl.3017
Signorovitch, J., Zhou, Z., Ryan, J., Anhorn, R., & Chawla, A. (2019). Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. J Med Econ, 22(2), 140-150. https://doi.org/10.1080/13696998.2018.1549056
Singal, G., Miller, P. G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., . . . Miller, V. A. (2019). Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Jama, 321(14), 1391-1399. https://doi.org/10.1001/jama.2019.3241
Teixidó, C., Vilariño, N., Reyes, R., & Reguart, N. (2018). PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol, 10, 1758835918763493. https://doi.org/10.1177/1758835918763493
Thomas, K., Gould, M. K., & Naegar, D. (2023, September 6, 2023). Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer. https://www.uptodate.com/contents/overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer
Volckmar, A. L., Leichsenring, J., Kirchner, M., Christopoulos, P., Neumann, O., Budczies, J., . . . Stenzinger, A. (2019). Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Int J Cancer, 145(3), 649-661. https://doi.org/10.1002/ijc.32133
Wang, Z., Yang, H., Luo, S., Liu, B., Zhang, N., Li, L., . . . Xie, X. (2017). Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. Lung Cancer, 112, 1-9. https://doi.org/10.1016/j.lungcan.2017.07.029
Medical Director review 8/2019
Specialty Matched Consultant Advisory Panel 3/2020
Medical Director review 3/2020
Medical Director review 7/2020
Specialty Matched Consultant Advisory Panel 3/2021
Medical Director review 3/2021
Medical Director review 8/2022
Medical Director review 7/2023
Medical Director review 7/2024